KPI data tables

Moderna operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Moderna Cash, Cash Equivalents and Investments (Quarterly) (usd_billions)
PeriodCash + investments ($B)
Q3 20267.976
Q2 20266.91
Q1 20267.456
Q4 20258.135
Q3 20256.647
Q2 20257.505
Q1 20258.393
Q4 20249.519
Q3 20249.202
Q2 202410.814
Q1 202412.161
Q4 202313.281
Q3 202312.846
Q2 202314.564
Q1 202316.365
Q4 202218.22
Q3 202217.003
Q2 202218.059
Q1 202219.286
Q4 202117.57
Q3 202115.348

Source: Moderna Exhibit 99.1 condensed consolidated balance sheets, cash plus investments plus investments, non-current (millions, divided by 1,000). SEC XBRL https://data.sec.gov/api/xbrl/companyfacts/CIK0001682852.json tags CashAndCashEquivalentsAtCarryingValue + AvailableForSaleSecuritiesDebtSecuritiesCurrent + AvailableForSaleSecuritiesDebtSecuritiesNoncurrent sum to the same liquidity total on overlapping quarter-ends; later 10-Q/10-K filing wins. Series Q3 2021–Q3 2026. Q4 2024: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/exhibit9912024q4pressrelea.htm ($1,927 + $5,098 + $2,494 million). Q1 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm ($1,623 + $4,352 + $2,418 million). Q2 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/exhibit9912025q2pressrelea.htm ($1,279 + $3,852 + $2,374 million). Q3 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/exhibit9912025q3pressrelea.htm ($1,132 + $3,372 + $2,143 million). Q4 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/exhibit9912025q4pressrelea.htm ($2,595 + $3,204 + $2,336 million). Q1 2026: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/exhibit9912026q1pressrelea.htm ($1,908 + $3,297 + $2,251 million). Q2 2026: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm ($1,723 + $3,415 + $1,772 million). Q3 2026: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000194/exhibit9912026q3pressrelea.htm ($1,195 + $3,976 + $2,805 million), filed 2026-11-06. Convertible notes: Form 8-K filed 1 Sep 2026, https://www.sec.gov/Archives/edgar/data/1682852/000119312526378505/d108896d8k.htm. Year-end 2026 outlook $8.1 to $8.3 billion is the Q3 2026 Exhibit 99.1 cash-and-investments framework and is not charted.

Moderna Net Product Sales by Product Type (Annual) (usd_billions)
PeriodCOVID (Spikevax and mNEXSPIKE)RSV (mRESVIA)
FY20251.810.008
FY20243.0840.025
FY20236.6710

Source: Moderna FY2025 Form 10-K Note, net product sales by product (https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/R24.htm and https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm). COVID includes Spikevax and mNEXSPIKE. FY2023 COVID $6,671 million, RSV not commercial. FY2024 COVID $3,084 million, RSV $25 million. FY2025 COVID $1,810 million, RSV $8 million. Totals $6,671 / $3,109 / $1,818 million match the net product sales line. Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/R11.htm) repeats that mCOMBRIAX was not commercialized as of 30 Jun 2026.

Moderna Other Revenue Composition (Annual) (usd_millions)
PeriodStand-ready manufacturingGrantCollaborationLicensing and royalty
FY202580221311
FY20240374842
FY2023094830

Source: Moderna FY2025 Form 10-K other-revenue note (https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/R24.htm). FY2023: grant $94 million, collaboration $83 million, licensing and royalty $0, stand-ready $0 (total $177 million). FY2024: grant $37 million, collaboration $48 million, licensing and royalty $42 million, stand-ready $0 (total $127 million). FY2025: grant $22 million, collaboration $13 million, licensing and royalty $11 million, stand-ready $80 million (total $126 million). Stand-ready is amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacity and pandemic readiness.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Moderna (MRNA) - KPIs | Sterling